

**Physician Consortium for Performance Improvement® (PCPI) Performance Measure Status Report**

<b>PCPI performance measure<sup>1</sup> (# of measures) (Lead Society)</b>	<b>NQF- endorsed™</b>	<b>AQA selected</b>	<b>2007 CMS PQRI</b>	<b>2008 CMS PQRI</b>
<b>Acute Otitis Externa / Otitis Media with Effusion (8 measures) (AAO-HNS Foundation)</b>				
AOE: Topical therapy		X		X
AOE: Pain assessment		X		X
AOE: Systemic antimicrobial therapy – avoidance of inappropriate use		X		X
OME: Diagnostic evaluation – assessment of tympanic membrane mobility		X		X
OME: Hearing test		X		X
OME: Antihistamines or decongestants- avoidance of inappropriate use		X		X
OME: Systemic antimicrobials – avoidance of inappropriate use		X		X
OME: Systemic corticosteroids – avoidance of inappropriate use		X		X
<b>Adult Diabetes (12 measures)</b>				
A1c management				
Lipid management				
Urine protein screening (2)				
Eye examination				
Foot examination				
Influenza immunization (2)				
Blood pressure management				
Aspirin use				
Smoking cessation (2)				
<b>Anesthesiology and Critical Care (3 measures) (ASA)</b>				
Prevention of ventilator-associated pneumonia – head elevation		X		X
Prevention of catheter-related bloodstream infections (CRBSI) – central venous catheter (CVC) insertion protocol		X		X
Perioperative temperature management		X		
<b>Asthma (2 measures)</b>				
Asthma assessment	X	X	X	X
Pharmacologic therapy	X	X	X	X
<b>Atrial Fibrillation (3 measures) (ACC / AHA)</b>				
Assessment of thromboembolic risk factors				
Chronic anticoagulation therapy				
Monthly international normalized ratio (INR) measurement				

**Physician Consortium for Performance Improvement® (PCPI) Performance Measure Status Report**

<b>PCPI performance measure<sup>1</sup> (# of measures) (Lead Society)</b>	<b>NQF- endorsed™</b>	<b>AQA selected</b>	<b>2007 CMS PQRI</b>	<b>2008 CMS PQRI</b>
<b>Chronic Kidney Disease (6 measures) (RPA)</b>				
Blood Pressure Management (as 2 measures in PQRI 08)		X		X
ACE Inhibitor (ACE) or Angiotensin Receptor Blocker (ARB) Therapy		X		X
Laboratory Testing (Calcium, Phosphorus, PTH and Lipid Profile)		X		X
Plan of Care - Anemia		X		X
Influenza Immunization		X		
Referral for AV Fistula		X		
<b>Chronic Obstructive Pulmonary Disease (12 measures)</b>				
Spirometry evaluation	X		X	X
Assessment of symptoms				
Smoking assessment				
Smoking cessation intervention				
Inhaled bronchodilator therapy	X		X	X
Assessment of oxygen saturation	X			
Long term oxygen therapy				
Recommendation of influenza immunization				
Influenza immunization administered				
Assessment of pneumococcus immunization status				
Pneumococcus immunization administered				
Pulmonary rehabilitation: exercise training recommended				
<b>Chronic Stable Coronary Artery Disease (10 measures) (ACC / AHA)</b>				
Blood pressure measurement				
Lipid profile		X		
Symptom and activity assessment	X			
Smoking cessation (2)				
Antiplatelet therapy	X	X	X	X
Drug therapy for lowering LDL-cholesterol	X	X		
Beta-blocker therapy – prior myocardial infarction (MI)	X	X	X	X
ACE inhibitor or ARB therapy	X	X		X
Screening for diabetes				

**Physician Consortium for Performance Improvement® (PCPI) Performance Measure Status Report**

<b>PCPI performance measure<sup>1</sup> (# of measures) (Lead Society)</b>	<b>NQF- endorsed™</b>	<b>AQA selected</b>	<b>2007 CMS PQRI</b>	<b>2008 CMS PQRI</b>
<b>Community-acquired Bacterial Pneumonia (12 measures)</b>				
Chest radiograph				
Assessment of co-morbid conditions				
Vital signs (also in Emergency Department measure set)				X
Assessment of oxygen saturation (also in Emergency Department measure set)				X
Assessment of mental status (also in Emergency Department measure set)				X
Assessment of hydration status				
Level of care rationale				
Empiric antibiotic (also in Emergency Department measure set)				X
Tobacco use assessment				
Tobacco cessation recommendation				
Assessment of influenza immunization status				
Assessment of pneumococcus immunization status				
<b>Emergency Medicine (9 measures) (ACEP)</b>				
Electrocardiogram performed for non-traumatic chest pain	X (2yr)	X	X	X
Aspirin at arrival for AMI	X (2 yr)	X	X	X
Electrocardiogram performed for syncope	X (2 yr)	X	X	X
Vital signs for community-acquired bacterial pneumonia	X (2 yr)	X	X	X
Assessment for oxygen saturation for community-acquired bacterial pneumonia	X (2 yr)	X	X	X
Assessment of mental status for community-acquired bacterial pneumonia	X (2 yr)	X	X	X
Empiric antibiotic for community-acquired bacterial pneumonia	X (2 yr)	X	X	X
Fibrinolytic therapy ordered within 20 minutes of ECG performed for AMI (QI)				
Care coordination for PCI (QI)				
<b>End Stage Renal Disease (6 measures) (RPA)</b>				
Influenza vaccination	X (2 yr)	X		X
Vascular access – patients receiving hemodialysis		X		X
Vascular access – patients receiving dialysis with a permanent catheter		X		
Plan of care for anemia		X		X
Plan of care for inadequate hemodialysis	X (2 yr)	X		X
Plan of care for inadequate peritoneal dialysis	X (2 yr)	X		X

**Physician Consortium for Performance Improvement® (PCPI) Performance Measure Status Report**

<b>PCPI performance measure<sup>1</sup> (# of measures) (Lead Society)</b>	<b>NQF- endorsed™</b>	<b>AQA selected</b>	<b>2007 CMS PQRI</b>	<b>2008 CMS PQRI</b>
<b>Eye Care (13 measures) (AAO)</b>				
<i>Primary open-angle glaucoma</i> : Optic nerve evaluation	X (2 yr)	X	X	X
<i>Primary open-angle glaucoma</i> : Reduction of intraocular pressure by 15% or documentation of a plan of care		X		
<i>Primary open-angle glaucoma</i> : Counseling on glaucoma		X		
<i>Age-related macular degeneration</i> : Counseling on Antioxidant Supplements		X	X	
<i>Age-related macular degeneration</i> : Dilated macular examination	X (2 yr)	X	X	X
<i>Cataracts</i> : Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures		X		
<i>Cataracts</i> : 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery		X		
<i>Cataracts</i> : Comprehensive Pre-operative Assessment for Cataract Surgery with Intraocular (IOL) Placement		X		
<i>Diabetic retinopathy</i> : Documentation of presence or absence of macular edema and level of severity of retinopathy	X (2 yr)	X	X	X
<i>Diabetic retinopathy</i> : Communication with the physician managing ongoing diabetes care	X (2 yr)	X	X	X
<b>Gastroesophageal Reflux Disease (5 measures) (AGA Institute)</b>				
Assessment for alarm symptoms		X	X	
Upper endoscopy for patients with alarm symptoms		X	X	
Biopsy for Barrett's esophagus		X	X	
Barium swallow – inappropriate use		X	X	
Continuous medication therapy – assessment of GERD symptoms		X		X
<b>Geriatrics (9 measures) (AGS)</b>				
Medication reconciliation	X (2 yr)	X	X	X
Advance care plan	X (2 yr)	X	X	X
Assessment of presence or absence of urinary incontinence in women aged 65 years and older	X (2 yr)	X	X	X
Characterization of urinary incontinence in women aged 65 years and older	X (2 yr)	X	X	X
Plan of care for urinary incontinence in women aged 65 years and older	X (2 yr)	X	X	X
<i>Urinary incontinence – medication overuse in women aged 65 years and older (QI)</i>				
Screening for future fall risk	X (2 yr)	X	X	X
Risk Assessment for Falls		X		
Plan of Care for Falls		X		

**Physician Consortium for Performance Improvement® (PCPI) Performance Measure Status Report**

<b>PCPI performance measure<sup>1</sup> (# of measures) (Lead Society)</b>	<b>NQF- endorsed™</b>	<b>AQA selected</b>	<b>2007 CMS PQRI</b>	<b>2008 CMS PQRI</b>
<b>Heart Failure (11 measures) (ACC / AHA)</b>				
Left ventricular function assessment	X	X		
Weight measurement	X			
Blood pressure measurement				
Assessment of clinical symptoms of volume overload (excess)	X			
Assessment of activity level	X			
Assessment of clinical signs of volume overload (excess)				
Patient education	X			
Beta-blocker therapy	X	X	X	X
ACE inhibitor or ARB therapy	X	X	X	X
Warfarin therapy for patients with atrial fibrillation	X	X		
Laboratory tests				
<b>Hematology (4 measures) (ASH)</b>				
<i>Myelodysplastic syndrome (MDS) and acute leukemias</i> : Baseline cytogenetic testing performed on bone marrow		X	X	X
<i>MDS</i> : Documentation of iron stores in patients receiving erythropoietin therapy		X	X	X
<i>Multiple myeloma</i> : Treatment with bisphosphonates		X	X	X
<i>Chronic lymphocytic leukemia</i> : Baseline flow cytometry		X	X	X
<b>Hepatitis C (11 measures) (AGA Institute)</b>				
Testing for chronic hepatitis C (HCV): confirmation of hepatitis C viremia		X		X
HCV RNA testing before initiating treatment		X		X
HCV genotype testing prior to treatment		X		X
Consideration for antiviral therapy		X		X
Combination antiviral therapy		X		
HCV RNA testing at week 12 of treatment		X		X
Hepatitis A vaccination		X		two measures combined for PQRI '08
Hepatitis B vaccination		X		
Education regarding risk of alcohol consumption		X		X
Counseling regarding use of contraception prior to antiviral treatment		X		X
HCV RNA testing at week 24 of treatment (Quality Improvement Only)				
<b>Hypertension (2 measures) (ACC / AHA)</b>				
Blood pressure measurement	X			
Plan of care	X			

**Physician Consortium for Performance Improvement® (PCPI) Performance Measure Status Report**

<b>PCPI performance measure<sup>1</sup> (# of measures) (Lead Society)</b>	<b>NQF- endorsed™</b>	<b>AQA selected</b>	<b>2007 CMS PQRI</b>	<b>2008 CMS PQRI</b>
<b>Major Depressive Disorder (5 measures)</b>				
Diagnostic evaluation	X	X		X
Suicide assessment	X	X		X
Severity classification				
Treatment: Psychotherapy, medication management, and/or electroconvulsive therapy				
Continuation of antidepressant medication				
<b>Melanoma (4 measures) (AAD)</b>				
Melanoma Follow-Up Measures		X		
Melanoma Continuity of Care – Recall System		X		
Melanoma Coordination of Care		X		
Overutilization of Imaging Studies in Stage 0-1A Melanoma		X		
<b>Nuclear Medicine (Society of Nuclear Medicine)</b>				
Correlation With Existing Imaging Studies for All Patients Undergoing Bone Scintigraphy		X		
Communication to Referring Physician of Patient's Potential Risk for Fracture for All Patients Undergoing Bone Scintigraphy				
<b>Oncology (10 measures) (ASTRO/ASCO)</b>				
Cancer stage documented		X		
Hormonal therapy for stage IC through IIIC, ER/PR positive breast cancer		X		X
Chemotherapy for Stage IIIA-Stage IIIC colon cancer patients		X		X
Plan for chemotherapy documented		X		X
Treatment summary documented and communicated – Medical Oncology (Quality Improvement Only)				
Treatment summary communicated – Radiation Oncology		X		
Normal tissue dose constraints specified		X		
Pain Intensity Quantified		X		
Plan of Care for Pain		X		
Pathology report (Quality Improvement Only)				
<b>Osteoarthritis (7 measures) (AAOS)</b>				
Symptom and functional assessment	X	X		X
Physical examination of the involved joint				
Assessment for use of anti-inflammatory or analgesic OTC medications	X	X		
Anti-inflammatory/analgesic therapy				
Non-steroidal anti-inflammatory drug (NSAID) risk assessment				
Gastrointestinal prophylaxis				
Therapeutic exercise for the involved joint				

**Physician Consortium for Performance Improvement® (PCPI) Performance Measure Status Report**

<b>PCPI performance measure<sup>1</sup> (# of measures) (Lead Society)</b>	<b>NQF- endorsed™</b>	<b>AQA selected</b>	<b>2007 CMS PQRI</b>	<b>2008 CMS PQRI</b>
<b>Osteoporosis (6 measures) (AAFP / AAOS / AACE / ACR / TES)</b>				
Communication with the physician managing on-going care post fracture	X (2 yr)	X	X	X
Screening or therapy for women aged 65 years and older	X (2 yr)	X	X	X
Management following fracture	X (2 yr)	X	X	X
Pharmacological therapy	X (2 yr)	X	X	X
Counseling for vitamin D, calcium intake and exercise		X	X	
Glucocorticosteroids and other secondary causes (QI)				
<b>Outpatient Parenteral Antimicrobial Therapy (5 measures) (IDSA)</b>				
Plan of care documentation at initial visit (QI)				
Maintenance visit – history (QI)				
Maintenance visit – physical examination (QI)				
Laboratory testing – CBC (QI)				
Laboratory testing – creatinine or GFR (QI)				
<b>Pathology (2 measures) (CAP)</b>				
Breast cancer resection pathology reporting – pT category and pN category with histologic grade		X		X
Colorectal cancer resection pathology reporting – pT category and pN category with histologic grade		X		X
<b>Pediatric Acute Gastroenteritis (4 measures) (AAP / AAFP)</b>				
Documentation of hydration status				
Weight measurement				
Recommendation of appropriate oral rehydration solution				
Education				
<b>Perioperative Care (6 measures) (ACS)</b>				
Timing of prophylactic antibiotics – ordering physician	X (2 yr)	X	X	X
Timing of prophylactic antibiotics – administering physician	X (2 yr)	X	X	X
Selection of prophylactic antibiotic – first or second generation cephalosporin	X (2 yr)	X	X	X
Discontinuation of prophylactic antibiotics (non-cardiac procedures)	X (2 yr)	X	X	X
Discontinuation of prophylactic antibiotics (cardiac procedures)	X (2 yr)	X	X	X
Venous thromboembolism (VTE) prophylaxis	X (2 yr)	X	X	X
<b>Prenatal Testing (2 measures)</b>				
Anti-D immune globulin	X	X		
Screening for human immunodeficiency virus	X	X		

**Physician Consortium for Performance Improvement® (PCPI) Performance Measure Status Report**

<b>PCPI performance measure<sup>1</sup> (# of measures) (Lead Society)</b>	<b>NQF- endorsed™</b>	<b>AQA selected</b>	<b>2007 CMS PQRI</b>	<b>2008 CMS PQRI</b>
<b>Preventive Care and Screening (6 measures)</b>				
<i>Colorectal cancer screening assessment</i> : Colorectal cancer screening				
<i>Adult influenza immunization</i> : Influenza immunization received	X			X
<i>Problem drinking</i> : Queried about and screened for problem drinking				
<i>Screening mammography</i> : Female patients who received a mammogram				
<i>Tobacco use</i> : Queried about tobacco use	X	X		X
<i>Tobacco use</i> : Tobacco users who received cessation intervention	X			
<b>Prostate Cancer (6 measures) (AUA)</b>				
Initial evaluation		X		X
Initial evaluation – new diagnosis		X		
Overuse measure – bone scan for staging low-risk patients		X		X
Treatment options for patients with clinically localized disease		X		X
Adjuvant hormonal therapy for high-risk patients		X		X
Three-dimensional radiotherapy		X		X
<b>Radiology (8 measures) (ACR)</b>				
Stenosis measurement in carotid imaging reports		X		
Mammography assessment category data collection		X		
Inappropriate use of "probably benign" assessment category in mammography screening		X		
Communication of suspicious findings from the diagnostic mammogram to the practice managing ongoing care		X		
Communication of suspicious findings from the diagnostic mammogram to the patient		X		
Reminder system for mammograms		X		
CT radiation dose reduction		X		
Exposure time reported for procedures using fluoroscopy		X		

**Physician Consortium for Performance Improvement® (PCPI) Performance Measure Status Report**

<b>PCPI performance measure<sup>1</sup> (# of measures) (Lead Society)</b>	<b>NQF- endorsed™</b>	<b>AQA selected</b>	<b>2007 CMS PQRI</b>	<b>2008 CMS PQRI</b>
<b>Stroke and Stroke Rehabilitation (9 measures) (AAN / ACR)</b>				
Deep vein thrombosis (DVT) prophylaxis for ischemic stroke and intracranial hemorrhage	X (2 yr)	X	X	X
Discharged on antiplatelet therapy	X (2 yr)	X	X	X
Anticoagulant therapy prescribed for atrial fibrillation	X (2 yr)	X	X	X
Tissue plasminogen activator (t-PA) considered	X ( 2 yr)	X	X	X
Screening for dysphagia	X (2 yr)	X	X	X
Consideration of rehabilitation services	X (2 yr)	X	X	X
Carotid imaging reports	X (2 yr)	X	X	X
CT or MRI reports	X ( 2 yr)	X	X	X
Avoidance of intravenous heparin (overuse measure) (QI)				
			<b>TOTAL Measure Sets:</b>	<b>33</b>
			<b>TOTAL MEASURES:</b>	<b>213</b>

Notes:

1 – The PCPI is currently evaluating the use of the phrases ‘overuse,’ ‘under use,’ ‘appropriate’ and ‘inappropriate’ in measure names. Measure names may be changed to ensure usage of these terms is consistent and precise.

2 – QI = Quality Improvement Only; not appropriate as an accountability measure(s)